| Haleon PLC (GB00BMX86B70) | |||
3,73 GBXStand (close): 03.07.25 |
 |
||
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 24.06.25 13:32:00 | Stewart Investors Identifies Six Global Companies Advancing Health Beyond Pharma |  |
| Brown & Brown, Cintas Corporation, Haleon, Linde, Raia Drogasil and Veeva Systems are making access to health and hygiene more equitable. EDINBURGH, Scotland, June 24, 2025 /PRNewswire/ -- While pharmaceutical drug pricing is making headlines amid President Trump's proposal to benchmark U.S. retail drug costs to international standards, less attention is being paid to attractive, albeit less-glamorous investment areas in the global health ecosystem, according to Stewart Investors, a long-only active global equity specialist. Stewart Investors, which manages US$16.5 billion in assets globally, has identified six companies, representing health-related businesses on three continents that are advancing health beyond pharmaceuticals. The companies – based in the U.S., the U.K. and Brazil – reflect Stewart Investors' bottom-up investment process for seeking quality holdings that can generate long-term profitability and contribute meaningfully to sustainable development. "The topic of health care, especially from an investor's perspective, is often dominated by pharmaceuticals, but those companies represent only a fraction of the investable health-related universe," said Clare Wood, portfolio specialist at Stewart Investors. "Recent news from the U.S. has highlighted the importance of access, availability, and the price of medicine. However, health is also about prevention, accessibility, security and environmental impact. Health equity is often thought of in relation to low- and middle-income countries, but there is a lot of health inequity in developed countries as well. We have identified several companies whose businesses are essential to building sustainable, inclusive health systems." Stewart Investors believes the following six companies (in alphabetical order) are helping to build healthier societies while embracing sustainable practices and providing attractive returns to investors: Brown & Brown: Brown & Brown (B&B), based in the U.S., is an insurance brokerage firm helping individuals, families and small/medium enterprises (SMEs) better handle costs associated with unforeseen events. B&B's clients provide health insurance and other coverage that supports employee health and well-being, improves employee retention, and reduces risks to the employer. B&B has been a Stewart Investors holding since January 2024. Its sales, free cash flow and earnings per share have increased at a compound annual rate of 15.1%1, 12.5%1 and 19.7%1 per year, respectively, over the five-year period ended Dec. 31, 2024.* Story Continues Cintas Corporation: Best known for corporate uniforms, U.S.-based Cintas is also a supplier of workplace hygiene and safety, providing cleaning supplies, personal protective equipment, first aid supplies, and fire safety products. Cintas helps a diverse customer base meet workplace health and safety standards and support employee well-being by reducing the spread of illness-causing germs. Cintas' rental business model applies the circular economy principles of reuse, reduce and recycle. It supplies, launders, repairs and returns clean uniforms and cleaning products to its clients. Its laundering service helps to extend the life of uniforms, reducing textile waste and offers a safer and more efficient alternative to home laundry, using approximately half the water and energy and about 16% less detergent compared with home laundering methods. For the five-year period ended May 31, 2024* Cintas' sales, free cash flow and earnings per share grew at a compound annual rate of 6.8%2, 16.1%2 and 13.7%2, respectively. It has been a Stewart Investors holding since January 2025. Haleon: Based in the U.K., Haleon is a global leader in consumer health, focused on providing oral health products, vitamins, minerals, supplements and over-the-counter medicine. Its brands include Sensodyne, Advil, Voltaren and Centrum. The company empowers individuals to take charge of their wellness, reducing strain on healthcare systems through prevention and self-care. Spun out of GSK in 2022, Haleon is the only company in the world focused purely on consumer health.3 A Stewart Investors holding since November 2024, Haleon's sales, free cash flow and earnings per share increased at a compound annual rate of 5.8%4, 24.5%4 and 17.3%4, respectively, for the five-year period ended Dec. 31, 2024.* Linde: Linde, based in the U.K., produces essential gases that are necessary inputs for a variety of end customers including the healthcare sector. Linde supports healthcare by supplying oxygen and cryogenic gases essential for surgery, intensive care unit care, and the storage and transport of vaccines and biologics. It also supplies oxygen to patients in hospitals and care homes. A Stewart Investors holding since November 2023, Linde's sales, free cash flow and earnings per share rose at a compound annual rate of 3.2%5, 14.5%5 and 26.6%5, respectively, for the five-year period ended Dec. 31, 2024.* Raia Drogasil: As Brazil's largest retail pharmacy chain, Raia Drogasil has positioned itself as a front-line healthcare provider, widening access to medicine while reducing prices to end users through economies of scale. Its in-store services and growing digital footprint make basic health care more accessible and affordable. A Stewart Investors holding since October 2014, the company has increased its sales, free cash flow and earnings per share at a compound annual rate of 17.2%6, 26.3%6 and 10%6 for the five-year period ended Dec. 31, 2024.* Veeva Systems: A cloud-based software firm powering efficiency in clinical trials and drug development, U.S.-based Veeva Systems helps researchers collaborate securely and streamline data, accelerating the path from lab to treatment for pharmaceutical and life sciences industry applications. Veeva is a founder-run public benefit corporation (PBC)—a for-profit company that is legally required to consider both financial returns and a positive impact on society or the environment in its decisions. A Stewart Investors holding since November 2019, Veeva Systems' sales, free cash flow and earnings per share rose at a compound annual rate of 20%7, 19.8%7 and 17.8%7, respectively, for the five-year period ended Dec. 31, 2024.* "Health is shaped not only by medicine, but also by infrastructure, access, prevention, and protection," Wood said. "These six companies have demonstrated financial resilience and are a positive influence on global health." The six companies identified were gathered from the larger universe of approximately 200 holdings across Stewart Investors' emerging markets, regional and worldwide equity strategies. Investors can find Stewart Investors' holdings in its Portfolio Explorer tool, which details the investment team's approach, identifies the companies held in the firm's strategies, and explains how Stewart Investors believes these stocks are contributing to sustainable development. Launched in 2021, Portfolio Explorer was developed to help investors explore strategies, companies, countries and sustainability issues of interest in four views: map, human development pillars, climate solutions and sustainable development goals. Each of the four views contains relevant sub-categories. About Stewart Investors Stewart Investors, with US$16.5 billion in assets under management as of March 31, 2025, is a long-only active global equity specialist. It manages a range of worldwide, emerging markets and regional strategies on behalf of institutional and individual clients globally. Based in Edinburgh, the firm also has offices in Frankfurt, Hong Kong, London, New York, Singapore and Sydney. For more information, visit: www.stewartinvestors.com. U.S. Media Contacts Margaret Kirch Cohen Newton Park PR margaret@newtonparkpr.com +1 847 507 2229 Kathy Panagopoulos Newton Park PR kathy@newtonparkpr.com +1 773 710 7433 Notes *Most recent year-end financial data available 1 Brown & Brown 2024 Annual Report: https://investor.bbrown.com/static-files/5bf52535-c001-4510-b057-6be5967dbaba 2 Cintas Corporation 2024 Annual Report: https://www.cintas.com/docs/default-source/investor-relations/annual-reports/2024-form-10-k.pdf?sfvrsn=684c93e2_1 3 Haleon corporate web site: https://www.haleon.com/who-we-are 4 Haleon 2024 Annual Report: https://www.haleon.com/content/dam/haleon/corporate/documents/investors/oar-2024/haleon-annual-report-and-form-20F-2024.pdf.downloadasset.pdf 5 Linde 2024 Annual Report: https://assets.linde.com/-/media/global/corporate/corporate/documents/investors/full-year-financial-reports/2024-annual-report-to-shareholders.pdf 6 Raia Drogasil 4Q2024 and year-end 2024 Financial Statements: https://ir.rdsaude.com.br/Download.aspx?Arquivo=e70PFwSs+83NQK3emu77vA==&linguagem=en 7 Veeva Systems 2024 Annual Report & Proxy Statement: https://s2.q4cdn.com/456805372/files/doc_financials/2024/ar/veeva-2024-annual-report-and-proxy-statement.pdf Important Information This press release is intended for information only, aimed solely at the media and should not be further distributed to individual and/or corporate investors, and financial advisers and/or distributors. This document has been prepared for general informational purposes. It does not purport to be comprehensive or to give advice. This is not an offer document and does not constitute an offer or invitation or investment recommendation to distribute or purchase securities, shares, units or other interests or to enter into an investment agreement. The information contained within this document has been obtained from sources that we believe to be reliable and accurate at the time of issue but no representation or warranty, express or implied, is made as to the fairness, accuracy, or completeness of the information. Reference to specific securities (if any) is included for the purpose of illustration only and should not be construed as a recommendation to buy or sell the same. All securities mentioned herein may or may not form part of the holdings of Stewart Investors' portfolios at a certain point in time, and the holdings may change over time.Cision View original content:https://www.prnewswire.com/news-releases/stewart-investors-identifies-six-global-companies-advancing-health-beyond-pharma-302489713.html SOURCE Stewart Investors |
||
| 24.06.25 12:00:00 | HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER | |
| LONDON, June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.Carl Haney This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Brian McNamara, Haleon's Chief Executive Officer commented: "I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon's significant potential through our new Win as One strategy. "I want to take this opportunity to thank Franck for his significant contribution to Haleon over the last six years. He has played an important role in the lead up to and beyond separation to move our innovation agenda forward and prepare us for the next phase of our journey. On behalf of everyone at Haleon, I wish him the very best for the future." Carl Haney commented: "I am hugely excited to be joining Haleon at such an important stage of its journey, as it looks to capitalise on the significant opportunities ahead and continues its transformation into a world class consumer company. I am incredibly passionate about the role that R&D can play in delivering Haleon's ambitions and its purpose of delivering better everyday health with humanity. I am very much looking forward to meeting the team and getting started in August." About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding. Photo - https://mma.prnewswire.com/media/2717039/Haleon.jpgCision View original content to download multimedia:https://www.prnewswire.com/news-releases/haleon-appoints-carl-haney-as-chief-rd-officer-302488742.html SOURCE Haleon |
||
| 01.05.25 12:00:00 | Brightseed and Haleon Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation |  |
| Forager® AI Platform to Enable Haleon’s Scientists to Unlock the Power of Nature for Consumer Health LONDON & SAN FRANCISCO, May 01, 2025--(BUSINESS WIRE)--Haleon (LSE: HLN), a global leader in consumer health, and Brightseed, the pioneer in AI-driven discovery of bioactive compounds, announced a new collaboration to advance the discovery of plant-based, small molecules with the potential to improve human health. This partnership will leverage Brightseed’s proprietary AI platform, Forager®, as a solution to accelerate scientific insights into the natural world and support Haleon’s mission to deliver innovative, science-led health solutions. Forager is a cutting-edge, artificial intelligence platform that maps bioactives—compounds in plants and other natural sources that influence human biology—and identifies their mechanisms of action. In addition to this collaboration agreement, Brightseed will work with Haleon to make Forager directly accessible to Haleon’s scientists, enabling efficient natural bioactive discovery by integrating AI-powered discovery into their research and product development pipelines. "We are thrilled with this partnership that augments our scientific capabilities towards groundbreaking advancements," said Sandrine Alvarado, VP and Head of Future Horizons R&D at Haleon. "This collaboration is pivotal in accelerating discoveries and innovations that are firmly rooted in superior, trusted science and the highest standards of scientific integrity." Brightseed’s AI-driven approach to bioactive discovery has already yielded key insights into plant compounds with potential applications across metabolic health, gut health, immunity, and more. This collaboration aligns with Haleon’s commitment to science-backed innovation and the pursuit of next-generation natural health solutions. "Forager’s AI not only accelerates innovation, it also expands possibilities in ways that would have been otherwise intractable," said Lee Chae, Co-Founder and CEO at Brightseed. "With this collaboration, Haleon is poised to translate those possibilities into an engine for growth. By integrating Forager® into its research ecosystem, Haleon is furthering its commitment to improving everyday health with scientifically validated, nature-inspired solutions." About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding. Story Continues About Brightseed Brightseed is an AI-driven biosciences company unlocking the power of nature to improve human health. Its proprietary AI platform, Forager®, identifies bioactive compounds in plants and natural sources and maps their impact on human biology at an unprecedented scale. Brightseed partners with global companies in consumer health, functional ingredients, and nutrition to accelerate the discovery and commercialization of science-backed health solutions. For more information, visit Haleon.com and Brightseedbio.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501237081/en/ Contacts Media Contacts Haleon Gemma Thomas gemma.x.thomas@haleon.com Brightseed press@Brightseedbio.com View Comments |
||
| 21.03.25 16:26:00 | Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals | |
| This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3 glomerulopathy (C3G). Pfizer PFE sold its remaining 7.3% stake in Haleon, thus fully exiting the consumer health company. Sanofi SNY and AstraZeneca AZN announced small acquisition deals. Here's a recap of the week’s most important stories. Pfizer Divests Remaining Stake in Haleon Pfizer divested 7.3% remaining stake in Haleon, or approximately 662 million shares, to institutional investors and Haleon itself for £3.85 per ordinary share (around £2.5 billion). Pfizer sold 618 million ordinary shares of HLN to institutional investors worth around $3.1 billion (around £2.4 billion). Per a previous share buyback plan, Pfizer sold around 44.14 million shares worth approximately $220 million (£170 million) directly to Haleon. Haleon was a consumer health joint venture jointly created by Pfizer and GSK in 2019. GSK owned a controlling stake of 68% in the Consumer Healthcare JV (CHC JV). GSK/Pfizer divested the CHC JV to form Haleon in July 2022. GSK, which initially owned a nearly 13% stake in Haleon, sold its entire stake in May 2024. Pfizer originally held a 32% stake in Haleon, which it had started gradually reducing since 2022. FDA Approves J&J’s Tremfya for Crohn’s Disease The FDA approved J&J’s IL-23 inhibitor Tremfya for its second IBD condition — moderately to severely active CD for both subcutaneous (SC) and intravenous (IV) induction regimens. The approval for the CD indication was based on data from the phase III GALAXI and GRAVITI studies, which demonstrated the robust efficacy of SC or IV Tremfya in achieving clinical and endoscopic endpoints. Tremfya was approved for its first IBD condition, moderately to severely active ulcerative colitis (“UC”), in September 2024. It is already approved to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. CD marks the fourth indication for Tremfya in the United States. Tremfya is under review in the EU for both UC and CD indications. J&J announced that the FDA has granted Fast Track designation to its key pipeline candidate, nipocalimab, for treating moderate-to-severe Sjögren’s disease (SjD), a chronic autoantibody disease with no approved advanced therapies. Earlier, the FDA had granted Breakthrough Therapy Designation to nipocalimab for SjD in November 2024. In February this year, J&J had announced positive top-line data from a phase II study in SjD. Nipocalimab met the primary endpoint of the phase II DAHLIAS dose-ranging study in SjD. J&J is now enrolling patients in the phase III DAFFODIL study Story Continues Nipocalimab is in mid- and late-stage development for several rare autoantibody-driven rare diseases. FDA Approves NVS’ Fabhalta for Rare Kidney Disease The FDA approved Novartis’ Fabhalta for the treatment of adults with C3G, an ultra-rare, progressive kidney disease. The approval for the C3G indication was based on robust data from the APPEAR-C3G study. With the approval, Fabhalta, an oral alternative complement pathway inhibitor, became the first and the only drug approved to treat the underlying cause of C3G. Similar applications seeking approval of Fabhalta for C3G are under review in the EU, China and Japan. The drug is already approved for treating paroxysmal nocturnal hemoglobinuria and for reducing the risk of rapid disease progression in proteinuria adults with primary IgA nephropathy. Novartis is evaluating Fabhalta in a broad range of rare kidney diseases, including atypical hemolytic uremic syndrome, immune complex membranoproliferative glomerulonephritis and lupus nephritis. AZN to Acquire EsoBiotec; EU Nod for Imfinzi Expanded Use AstraZeneca announced a definitive agreement to acquire Belgium-based, EsoBiotec, a leading vivo cell therapy company for a total consideration of up to $1 billion in cash and on a debt-free basis. The acquisition will integrate EsoBiotec’s proprietary ENaBL platform, used to develop transformative cell therapy treatments, which can be delivered in just minutes, in contrast to traditional cell therapies that take weeks. The transaction is expected to be closed in the second quarter of 2025. AstraZeneca is in-licensing worldwide rights to Alteogen’s novel hyaluronidase enzyme, ALT-B4, for developing subcutaneous formulations of multiple oncology assets. ALT-B4 has been developed utilizing the Hybrozyme platform technology. For the deal, AstraZeneca will make an undisclosed upfront payment to Alteogen, with the latter also being entitled to development, regulatory and sales-related milestone payments. The European Commission granted approval for the expanded use of AstraZeneca’s blockbuster drug, Imfinzi, as a monotherapy for the treatment of adults with limited-stage small cell lung cancer in patients whose disease has not progressed following platinum-based chemoradiation therapy. This approval was based on data from the phase III ADRIATIC study. The FDA approved Imfinzi for a similar indication in December 2024. AstraZeneca’s pipeline candidate, eneboparatide, met its primary endpoint of normalizing serum calcium levels at 24 weeks, with statistical significance, in the phase III CALYPSO study. The study evaluated eneboparatide in adults with chronic hypoparathyroidism, a rare endocrine disease. Eneboparatide was added to AstraZeneca’s pipeline following the acquisition of Amolyt Pharma last year. The study will continue for 52 weeks to further characterize the risk-benefit profile, after which the data will be shared with global health authorities. SNY’s New Acquisition to Strengthen Immunology Pipeline Sanofi is acquiring private biotech, Dren Bio’s targeted bispecific myeloid cell engager (MCE), DR-0201 for an upfront payment of $600 million. In clinical studies, DR-0201 has shown robust B-cell depletion. B-Cell depletion is believed to have the potential to reset the adaptive immune system, which can be a game changer for treating autoimmune diseases, particularly for patients refractory to existing treatments. DR-0201 is being evaluated in two phase I studies. In addition to the upfront payment, Dren Bio will also be entitled to potential milestone payments of up to $1.3 billion. The transaction is expected to be closed in the second quarter of 2025. Pfizer, Novartis, Sanofi and J&J carry a Zacks Rank #3 (Hold) each, while AstraZeneca is a #4 Ranked (Sell) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The NYSE ARCA Pharmaceutical Index has risen 2.09% in the past five trading sessions. Large Cap Pharmaceuticals Industry 5YR % ReturnLarge Cap Pharmaceuticals Industry 5YR % Return Large Cap Pharmaceuticals Industry 5YR % Return Here’s how the eight major stocks performed in the previous five trading sessions.Zacks Investment Research Image Source: Zacks Investment Research In the last five trading sessions, Lilly rose the most (5.1%) while JNJ, MRK and AZN were flat. In the past six months, AbbVie rose the most (9.4%), while Novo Nordisk declined the most (36.3%). (See the last pharma stock roundup here: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update) What's Next in the Pharma World? Watch this space for regular pipeline and regulatory updates next week. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 21.03.25 13:44:08 | Sensodyne-maker axes diversity targets from bonuses | |
| Haleon sign Haleon is to axe diversity targets from its executive bonus scheme in the latest sign that UK businesses are rowing back on DEI. The Sensodyne-maker has confirmed that its chief executive and chief financial officer will no longer have to meet gender representation targets to maximise their pay. The diversity targets had formed part of the company’s share scheme, which accounts for a significant portion of executive remuneration. Last year, Brian McNamara, the company’s chief executive, secured share payouts worth £6m, taking his total pay package for the year to £9m. Under the 2022-2024 share plan, executives were set targets for women to hold at least 44.5pc of leadership roles, which the company subsequently met. However, Haleon – which was split out from GSK in 2022 – has now removed the gender diversity target for the coming year to “ensure continued compliance with requirements in countries in which we operate”. It follows a pushback from the US government over corporate diversity initiatives, spearheaded by Donald Trump since coming to power in January. The move comes just weeks after GSK, which counts the US government as one of its largest customers, also revealed it was watering down diversity targets for its executive bonus scheme. The London-listed drugmaker said it was putting diversity activities on pause to review them, adding: “We have to ensure we remain compliant with the law in the countries in which we operate, including the US. We are consulting and talking to our people about all of this.” Mr Trump has sought to ban federal agencies and contractors from setting diversity, equality and inclusion (DEI) targets, while he has also signed into law new rules that require companies to scrap targets. This shift has already filtered through to the UK, with a recent poll of 500 City executives showing that one in three bosses now believe DEI has gone too far. Figures compiled for The Telegraph by job site Adzuna last month revealed that hiring for DEI roles has fallen by a third since last year. Following the latest change in policy, a Haleon spokesman added: “Haleon is committed to an inclusive organisation that represents the consumers and communities who rely on our brands. This commitment has not changed.” View Comments |
||
| 20.03.25 12:45:00 | Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B | |
| Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or approximately 662 million shares, for £3.85 per ordinary share (around £2.5 billion). With this move, Pfizer has fully exited its stake in Haleon, which makes popular brands such as Advil painkiller and Sensodyne toothpaste. Details of PFE’s HLN Stake Divestment Pfizer sold 618 million ordinary shares of HLN to institutional investors worth around $3.1 billion (around £2.4 billion). Per a previous share buyback plan, Pfizer sold around 44.14 million shares worth approximately $220 million (£170 million) directly to Haleon. Haleon was a consumer health joint venture (JV), an over-the-counter (OTC) medicines business jointly created by Pfizer and GSK plc. GSK in 2019. GSK owned a controlling stake of 68% in the Consumer Healthcare JV (CHC JV). GSK/Pfizer divested the CHC JV to form the company Haleon in July 2022. GSK, which initially owned a nearly 13% stake in Haleon, sold its entire stake in May 2024. Pfizer originally held a 32% stake in Haleon, which it has been gradually reducing since 2022. Following Pfizer’s divestment, BlackRock Investment Management (UK) Ltd, a unit of BlackRock, will become HLN’s largest shareholder with a stake of 5% Pfizer’s stock has declined 5.2% in the past year compared with a decrease of 3.8% for the industry.Zacks Investment Research Image Source: Zacks Investment Research Haleon’s stock has risen 24.5% in the past year compared with an increase of 9.5% for the industry.Zacks Investment Research Image Source: Zacks Investment Research Large Drugmakers Spin Off Consumer Units Lately, several large drugmakers have been divesting their Consumer divisions to help focus on their core pharmaceuticals business. In 2023, J&J JNJ separated its Consumer Health business into a newly listed company called Kenvue, which now operates as a separate and fully independent company. In mid-2024, J&J exited its remaining 9.5% stake in Kenvue’s common stock, bringing the separation to a close. With the complete separation of the Consumer Health segment, J&J has now become a two-sector company focused on the Pharmaceutical and MedTech fields. In October 2023, Sanofi announced that it intends to separate the Consumer HealthCare unit through the creation of a publicly listed entity headquartered in Paris to be called Opella. Sanofi has entered into an agreement with private equity firm CD&R for the sale of a 50% controlling stake in Opella. The transaction is expected to be closed in the second quarter of 2025. Story Continues PFE and HLN’s Zacks Rank Pfizer hasa Zacks Rank #3 (Hold), while Haleon is a Zacks Rank #4 (Sell) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Haleon PLC Sponsored ADR (HLN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 19.03.25 13:39:19 | Pfizer Sells Final Haleon Shares for $3.2B, Ends Stake in Consumer Healthcare Giant | |
| Pfizer (NYSE:PFE) has finalized the sale of its entire holding in Haleon (NYSE:HLN), generating approximately 2.5 billion ($3.24 billion), Reuters reported Wednesday, citing a bookrunner involved in the transaction. The pharmaceutical company, which co-founded Haleon alongside British drugmaker GSK (NYSE:GSK) in 2019, offloaded around 662 million shares, equal to a 7.3% stake. The shares were priced at 385 pence each. As part of the deal, Haleon repurchased 44 million shares directly from Pfizer, while institutional investors acquired the remaining 618 million. Bloomberg News previously disclosed on Tuesday that Pfizer planned to fully exit its stake in Haleon, a process that had been underway since the company's separation from GSK in 2022. With GSK having completed its divestment in May, BlackRock Investment Management (UK) Ltd., a subsidiary of BlackRock (NYSE:BLK), is set to become Haleon's largest shareholder, holding over 5% of its shares, according to Reuters, citing LSEG data. This article first appeared on GuruFocus. View Comments |
||
| 19.03.25 09:18:42 | Pfizer offloads final shares in Sensodyne maker Haleon | |
| US pharmaceutical firm Pfizer (PFE) has sold off its remaining stake in Sensodyne and Panadol maker Haleon (HLN.L) for around £2.5 billion. Haleon has agreed to buy back 44 million shares from Pfizer for £3.85 a share – totalling about £170 million – as part of the deal, with the remaining 618 million shares being sold to institutional investors. It sees Pfizer exit its investment in the UK consumer healthcare firm after the US group said in 2023 that it planned to reduce its holding gradually. Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer, sitting as a joint venture within GSK (GSK.L). It was then spun out of GSK as a standalone business and listed on the London Stock Exchange (LSEG.L) in July 2022. GSK initially retained a 12.9% stake in Haleon after the flotation, but offloaded its holding completely in May 2024 when it sold its last remaining shares for £1.2 billion. Pfizer had been left with a 7.3% stake in Haleon until the remaining stake sale. BlackRock Investment Management now becomes Haleon’s biggest shareholder, with a stake of more than 5% following the share sale by Pfizer. Haleon said the move to buy shares from Pfizer will make up some of its planned £500 million in share buybacks this year, which were announced on February 27. Brian McNamara, chief executive of Haleon, said: “Today’s transaction is an important milestone for the business and marks Pfizer fully exiting its stake in Haleon, having been at 32% at the time of demerger in July 2022. “Our participation in the offering is consistent with our disciplined capital allocation priorities, and supports our commitment to deliver attractive returns for shareholders, underpinned by a strong investment grade balance sheet. “Nearly three years on from demerger, Haleon is in a position of strength and is well placed to capitalise on the significant opportunities ahead.” View Comments |
||
| 19.03.25 07:26:43 | Pfizer sells entire Haleon stake for $3.24 billion | |
| (Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday. Under the deal, Sensodyne maker Haleon has agreed to buy back 44 million shares from Pfizer, currently its largest shareholder, with 618 million shares being sold to institutional investors. The total sale represents 7.3% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British drugmaker in 2022. GSK, which initially owned nearly 13% of the firm, sold its entire stake in May 2024. Following Pfizer's disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock, will become Haleon's largest shareholder with a more than 5% stake, according to data compiled by LSEG. BofA Securities, Citigroup Global Markets Limited, and Goldman Sachs International are joint global coordinators while Barclays and Deutsche Numis are joint bookrunners for the share sale. Haleon, which also makes Panadol and Advil painkillers, said in February its 2025 revenue and profit growth would be weighted to the second half of the year. ($1 = 0.7708 pounds) (Reporting by Anandita Mehrotra in Bengaluru; Editing by Mrigank Dhaniwala) View Comments |
||
| 18.03.25 19:22:00 | Teva Pharmaceutical Stock Scores RS Rating Upgrade | |
| Teva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading View Comments |
||
